Pharma Industry Leaders Warn Israel Risks Losing Ground in Clinical Trials

Industry leaders warn that Israel risks losing its competitive edge in clinical medical research to global rivals unless regulatory barriers are urgently dismantled and funding is expanded.

Pharma Industry Leaders Warn Israel Risks Losing Ground in Clinical Trials
Photo-illustration WireIsrael: AI Generated

Israel faces a critical juncture in maintaining its standing as an attractive global hub for clinical trials, according to industry leaders speaking at a healthcare conference. Kobi Tsurof, CEO of Pharma Israel, warned that once clinical research departs the country for competing nations, recovering that lost ground will prove exceedingly difficult.

Economic and Medical Impact of Clinical Trials

Clinical trials serve as a vital pillar in pharmaceutical development, enabling researchers to evaluate the safety and efficacy of emerging medications before commercial approval. Beyond advancing medical science and training clinical personnel, participation in trials often provides a critical lifeline for patients who have exhausted standard therapeutic options.

Tsurof highlighted an instance involving an oncology patient whose conventional treatments had all failed, noting that an early-phase clinical trial represented the individual's sole remaining chance for survival. Financially, multinational pharmaceutical companies pump hundreds of millions of shekels annually into Israeli medical facilities through these research partnerships.

According to a Ministry of Health report published last June, commercial agreements for hospital-based clinical studies reached approximately 1.055 billion shekels for 2025, marking an increase from 918 million shekels in 2024. These figures reflect approved contractual commitments rather than immediate cash transfers.

Resilience Amid Conflict and International Competition

Despite years of continuous security challenges and warfare, the local healthcare sector has managed to preserve the vast majority of its clinical trials. Tsurof cited the example of Rambam Health Care Campus in Haifa, where cancer patients maintained perfect 100 percent attendance at clinical trials even while missiles were intercepted from both Iran and Lebanon.

However, officials caution that wartime resilience does not guarantee future market dominance. Nations such as the United States, the United Kingdom, and China are channeling massive resources into attracting clinical research by streamlining regulatory approval processes and dismantling bureaucratic hurdles.

"We are no longer the only country that possesses accessible health data. While Israel was occupied managing successive crises from the pandemic onward, other nations advanced rapidly and invested capital," Tsurof told the audience.

Government Action and Regulatory Reform

In October, the government approved an initiative designed to eliminate regulatory bottlenecks in clinical trials by optimizing approval procedures and eliminating administrative redundancies across medical centers. The program has been allocated 25 million shekels for the 2026 and 2027 fiscal years.

While industry representatives welcomed collaboration with the Ministry of Health, they urged authorities to accelerate implementation and establish binding statutory deadlines. Observers argue that the Ministry of Finance must adequately resource the health administration to trim excessive regulations and ensure the country remains competitive on the global stage.

Related News